Fusion of Magnetic Resonance and Scintimammography Images for Breast Cancer Evaluation: A Pilot Study

详细信息    查看全文

• 作者：Giuliano Mendes Duarte MD (1)
  César Cabello PhD (1)
  Renato Zocchio Torresan PhD (1)
  Marcelo Alvarenga PhD (1)
  Gilliat H. Q. Telles MD (2)
  Susana Trigo Bianchessi MD (3)
  Nelson Caserta PhD (3)
  Silmara R. Segala MD (4)
  Mariana da Cunha Lopes de Lima MD (4)
  Elba Cristina Sá de Camargo Etchebehere PhD (4)
  Edwaldo E. Camargo PhD (4)
  Eduardo Tinois MD (5)
  
• 关键词：Breast cancer—Gadolinium—Magnetic resonance imaging—Scintimammography-9mTc ; sestamibi
• 刊名：Annals of Surgical Oncology
• 出版年：2007
• 出版时间：October 2007
• 年：2007
• 卷：14
• 期：10
• 页码：2903-2910
• 全文大小：402KB
• 参考文献：1. Holland R, Veling SH, Mravunac M, Hendriks JH. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer 1985; 56(5):979-0 CrossRef
  2. Kuroki Y, Nawano S, Hasebe T, Imoto S, Nasu K, Murakami K, Satake M, Sekiguchi R, Hayashi T. Efficacy of MR mammography (MRM) in providing preoperative locoregional information on breast cancer: correlation between MRM and histological findings. Magn Reson Med Sci 2002; 1(2):73-0 CrossRef
  3. Wasser K, Sinn HP, Klein SK, Junkermann H, Ludemann HP, Zuna I, et al. Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol 2002; 13(6):1213-3
  4. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. Am J Roentgenol 2002; 179(5):1193-
  5. Wiberg MK, Aspelin P, Sylvan M, Boné B. Comparison of lesion size estimated by dynamic MR imaging, mammography and histopathology in breast neoplasms. Eur Radiol 2003; 13(6):1207-2
  6. Kepple J, Layeeque R, Klimberg VS, Harms S, Siegel E, Gusmano F, Korourian S, Henry-Tillman RS. Correlation of magnetic resonance imaging and pathologic size of infiltrating lobular carcinoma of the breast. Am J Surg 2005; 190(4):623- CrossRef
  7. Palmedo H, Grünwald F, Bender H, Schomburg A, Mallmann P, Krebs D, et al. Scintimammography with technetium-99m methoxyisobutylisonitrile: comparison with mammography and magnetic resonance imaging. Eur J Nucl Med 1996; 23(8):940- CrossRef
  8. Tiling R, Khalkhail I, Sommer H, Moser R, Meyer G, Willemsen F, et al. Role of technetium-99m sestamibi scintimammography and contrast-enhanced magnetic resonance imaging for the evaluation of indeterminate mammograms. Eur J Nucl Med 1997; 24(10):1221- CrossRef
  9. Hata T, Takahashi H, Watanabe K, Takahashi M, Tagushi K, Itoh T, Todo S. Magnetic resonance imaging for evaluation of breast cancer: a comparative study with mammography and ultrasonography. J Am Coll Surg 2004; 198(2):190- CrossRef
  10. Lampe D, Hefler L, Alberich T, Sittek H, Perlet C, Prat X, et al. The clinical value of preoperative wire localization of breast lesions by magnetic resonance imaging—a multicenter study. Breast Cancer Res Treat 2002; 75(2):175- CrossRef
  11. Heywang-Kobrunner SH, Heinig A, Schaumloffel U, Viehweg P, Buchmann J, Lampe D, et al. MR-guided percutaneous excisional and incisional biopsy of breast lesions. Eur Radiol 1999; 9(8):1656-5 CrossRef
  12. Taillefer R. The role of ^99mtc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis. Sem Nucl Med 1999; 29(1):16-0 CrossRef
  13. Davis PL, Staiger MJ, Harris KB, Ganott MA, Klementaviciene J, McCarty KS Jr, Tobon H. Breast cancer measurements with magnetic resonance imaging, ultrasonography, and mammography. Breast Cancer Res Treat 1996; 37(1):1- CrossRef
  14. Boetes C, Mus RD, Holland R, Barentsz JO, Strijk SP, Wobbes T, Hendriks JH, Ruys SH. Breast tumors: comparative accuracy of MR imaging relative to mammography and US for demonstrating extent. Radiology 1995; 197(3):743-
  15. Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 2006; 33(3):254-2 CrossRef
  16. Fueger BJ, Weber WA, Quon A, Crawford TL, Allen-Auerbach MS, Halpern BS, Ratib O, Phelps ME, Czernin J. Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol 2005; 7(5):369-6 CrossRef
  17. Duarte GM, Santos CC, Torresan RZ, et al. Radioguided surgery using intravenous Tc^-99m sestamibi associated with breast magnetic resonance imaging for guidance of breast cancer resection. Breast J 2006; 12(3):202- CrossRef
  18. Tiling R, Linke R, Kessler M, Untch M, Sommer H, Brinkbaumer K, et al. Breast scintigraphy using 99m Tc- sestamibi—use and limitations. Nuklearmedizin 2002; 41(3):148-6
  19. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Drucker MJ, Livingston RB. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. Cancer 1999; 85(11):2410-3 CrossRef
  
• 作者单位：Giuliano Mendes Duarte MD (1)
  César Cabello PhD (1)
  Renato Zocchio Torresan PhD (1)
  Marcelo Alvarenga PhD (1)
  Gilliat H. Q. Telles MD (2)
  Susana Trigo Bianchessi MD (3)
  Nelson Caserta PhD (3)
  Silmara R. Segala MD (4)
  Mariana da Cunha Lopes de Lima MD (4)
  Elba Cristina Sá de Camargo Etchebehere PhD (4)
  Edwaldo E. Camargo PhD (4)
  Eduardo Tinois MD (5)
  
  1. Division of Oncology and Senology, Department of Obstetrics and Gynecology School of Medicine, Universidade Estadual de Campinas (Unicamp), Campinas, Brazil
  2. Department of Pathology School of Medicine, Universidade Estadual de Campinas (Unicamp), Campinas, Brazil
  3. Division of Magnetic Resonance Imaging, Department of Radiology, School of Medicine, Universidade Estadual de Campinas (Unicamp), Campinas, Brazil
  4. Division of Nuclear Medicine, Department of Radiology School of Medicine, Universidade Estadual de Campinas (Unicamp), Campinas, Brazil
  5. Centro de Engenharia Biomédica, Universidade Estadual de Campinas (Unicamp), Campinas, Brazil
  

文摘

Background To achieve a more specific method to estimate the real size of breast cancer, we have developed a method to fuse magnetic resonance imaging (MRI) and scintimammography (SM) images. The aim of this study was to assess the feasibility of this method and to evaluate its accuracy to measure the size of breast cancer compared with MRI alone, mammography, and clinical examination, employing pathologic size as the gold standard. Methods Twenty consecutive breast cancer women at stages IIA–IIIA, scheduled for mastectomies, underwent SM with 99mTc-sestamibi and MRI with gadolinium 2-0 days before surgery. All patients had had recent mammographies and were examined clinically. Software was developed in visual language to perform the fusion between MRI and SM images and tumor measurements (MRI/SM). The tumor size, in 3 diameters (anteroposterior, longitudinal, and transverse), for each examination was correlated with pathological measurements using linear regression. Results The MRI/SM technique was successfully performed in all patients, and the principal tumor was measured by this method. The MRI/SM cancer measurements correlated better with pathology than MRI, mammography, and clinical exam in all diameters analyzed (r?=?0.88, 0.81, 0.81; SE?=?0.11, 0.14, 0.11 in anteroposterior, longitudinal, and transverse diameters, respectively). Conclusions The MRI/SM is a feasible technique and appears to be more accurate than other examinations (MRI alone, mammography, and clinical exam) to measure breast cancer size.